# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Law Olmsted (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI022-SYN
- Date: 2026-06-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathan Calder, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week follow-up: results and MRI, diagnosis, and behavioral neurology consultation the same day. **S**

## History of present illness

Mr. Olmsted is a 73-year-old man evaluated four weeks ago for about two years of worsening memory, who returns with his caregiver for his results and is seen by behavioral neurology on the same day. Since the first visit he has stopped the glass of wine with dinner. He still repeats questions, loses track of letters and plans, and needs reminders for appointments; his caregiver now handles his medicines and bill paying. He has driven only short familiar routes, and once took a wrong turn near home this month. He sleeps well, has no hallucinations, acting out of dreams, falls, or urinary problems, and his mood is low at times when he thinks about leaving his work. The blood tests at the first visit were normal, and the brain MRI two weeks ago showed generalized and mild medial temporal atrophy with minor small-vessel change, without a stroke, tumor, or fluid build-up. **S**

| Element | Detail |
|---|---|
| Memory | Repeats questions; loses track of letters and plans; needs appointment reminders |
| Function | Caregiver now manages medicines and bill paying |
| Driving | Short familiar routes; one wrong turn near home this month |
| Behavior | Mild irritability and apathy; no hallucinations, dream enactment, or wandering |
| Results | Blood count, metabolic panel, vitamin B12, folate, and TSH normal; MRI with generalized and mild medial temporal atrophy and Fazekas grade 1 white-matter change |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Memory loss; no tremor, weakness, gait change, or falls |
| Psychiatric | Positive | Low mood at times about leaving his work; no hallucinations; no thoughts of self-harm |
| Genitourinary | Negative | No urgency or incontinence |
| Cardiovascular | Negative | No fainting or palpitations |

4 systems reviewed. **S**

## Current medications

- Donepezil 5 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 71.8 kg; BMI 23.4 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert, courteous, and articulate; repeats one question during the visit |
| Cardiovascular | Regular rhythm at 70 per minute; blood pressure 132/76 mmHg |
| Neurological | Oriented to person and place, not to date; no rest tremor, rigidity, or bradykinesia; normal gait, with no magnetic or shuffling quality |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Mild dementia, type undetermined** (F03.A0). Behavioral neurology confirms mild dementia (CDR 1), with IADL loss and intact basic ADL. No reversible cause was found on the blood tests, and the MRI shows no stroke, tumor, or hydrocephalus. The pattern of amnestic decline with executive difficulty and mild medial temporal atrophy fits Alzheimer's disease, but the MRI findings are not specific and no biomarker has been done, so the type remains undetermined. The diagnosis was shared with him and his caregiver, and he asked that it be explained to him plainly. **S**
   - Start donepezil 5 mg each morning, as neurology advises, and increase to 10 mg at the three-month visit if tolerated.
   - Stop driving now, as neurology advises; he agreed.
   - Avoid over-the-counter sleep aids, antihistamines such as diphenhydramine, and bladder or stomach medicines with anticholinergic effects.
   - Caregiver information on the Alzheimer's Association helpline and education programs.
   - Advance care planning at the three-month visit, while he can take full part.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Medication review with the AGS Beers Criteria (anticholinergic burden, sedatives, sleeping pills, antipsychotics) | Every visit | Completed today | No medicines on the Beers list; no over-the-counter sleep aids or antihistamines |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild irritability and apathy, unchanged; no hallucinations, delusions, agitation, or wandering |
| Medication safety | Cholinesterase inhibitor tolerability and benefit: heart rate, fainting, nausea, diarrhea, weight, sleep and dreams | Each follow-up on treatment | Completed today | Baseline before donepezil: heart rate 70, no fainting, weight 71.8 kg; starting 5 mg today |
| Medication safety | Antipsychotic appropriateness and taper review | Every visit if on an antipsychotic | Not indicated | Not on an antipsychotic; none is needed |
| Examination | Vascular risk-factor control (blood pressure, lipids, glucose, smoking) | Every visit | Completed today | Blood pressure 132/76 mmHg, above the 130/80 target only in the systolic reading, without treatment; glucose normal four weeks ago; never smoked; lipids not on record, to be drawn at the wellness visit |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Completed today | Home safety checklist given to his caregiver; stove use, night lighting, and medicine storage discussed |
| Survey | Cognitive test (MoCA) | Annually; every visit if a change is reported | Up to date | MoCA 19 of 30 four weeks ago |
| Survey | ADL (Katz) and IADL (Lawton-Brody) | Annually, and at any reported change | Up to date | Katz ADL 6 of 6 and Lawton IADL 5 of 8 four weeks ago |
| Survey | Dementia stage (CDR or FAST) | Annually | Completed today | CDR global 1 and FAST stage 4, confirmed by neurology |
| Survey | Depression screen (PHQ-9) | Annually, and at any reported change | Up to date | PHQ-9 6 four weeks ago, below 10; no thoughts of self-harm today |
| Examination | Fall-risk assessment (Timed Up and Go, gait and balance) | Annually | Up to date | Timed Up and Go 11 seconds four weeks ago; no falls |
| Examination | Driving safety (CDR-based) | At diagnosis and annually | Completed today | CDR 1 with a wrong turn near home: high risk; neurology advises stopping, and he agreed to stop today |
| Self-management | Firearms, wandering, and financial safety | At diagnosis and with any change | Completed today | No firearms in the home; no wandering, and a medical identification bracelet advised; his caregiver oversees bill paying with his agreement |
| Survey | Caregiver burden (Zarit Burden Interview) and caregiver needs | At diagnosis, then every 6 to 12 months | Deferred | Not done at the diagnosis visit, a deviation from the protocol: the visit ran long with the diagnosis discussion and consultation, and the questionnaire sent home was not returned. No caregiver crisis followed. Corrective action: the Zarit Burden Interview is scheduled at the three-month visit and then with each six-month review |
| Self-management | Advance care planning and goals of care | At diagnosis, then annually and at stage changes | Due | Diagnosis disclosed today; advance care planning booked for the three-month visit so he can take part while he is able |
| Laboratory | TSH, vitamin B12, blood count, and metabolic panel | At diagnosis; repeat only with acute cognitive worsening | Up to date | Normal four weeks ago, including vitamin B12 410 pg/mL and TSH 1.9 |
| Laboratory | Syphilis and HIV testing | Only with risk factors or atypical features | Not indicated | No risk factors, no atypical or rapid course, and no neurological signs |
| Imaging | Structural brain MRI, non-contrast | Once at diagnosis; repeat only with an atypical course or focal change | Completed today | MRI two weeks ago reviewed: generalized atrophy, mild medial temporal atrophy, Fazekas grade 1; no infarct, mass, or hydrocephalus; no repeat planned |
| Laboratory | Amyloid or tau biomarkers (blood, CSF, or amyloid PET) and APOE genotype | Before anti-amyloid therapy, or when the result would change care | Not indicated | Offered by neurology; he and his caregiver chose not to pursue biomarkers now, because he does not want anti-amyloid infusions and their MRI monitoring, and the result would not change the rest of his care. Can be revisited |
| Imaging | Anti-amyloid antibody therapy with ARIA surveillance MRI | Only if anti-amyloid therapy is started | Not indicated | Not chosen after discussion with neurology |
| Self-management | Lifestyle: aerobic exercise about twice a week, hearing, vision, sleep, social engagement | Ongoing | Completed today | Daily walks with company; hearing and vision reviewed at the wellness visit; social contact encouraged |
| Referral | Dementia care navigation and caregiver support program | At enrollment, with ongoing support | Completed today | Alzheimer's Association helpline and education program information given to his caregiver |
| Referral | Behavioral neurology consultation | At diagnosis, then yearly or with a change | Completed today | Seen today: mild dementia of undetermined type confirmed; donepezil and driving cessation advised |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Due | Influenza vaccine given last autumn; others at the wellness visit |

## Goal progress

- Complete the reversible-cause tests and brain MRI and discuss the diagnosis with him and his caregiver by the four-week visit. Outcome by 2026-06-02: Tests and MRI showed no reversible cause; diagnosis of mild dementia of undetermined type discussed with both. **S**
- A safety plan in place by the three-month review: no driving, medicines supervised, finances overseen, and medical identification worn. In progress; target 2026-08-04. **S**
- Donepezil at 10 mg daily without side effects and with resting heart rate 55 or above by the six-month review. In progress; target 2026-10-27. **S**
- Caregiver burden assessed and support in place by the six-month review. In progress; target 2026-10-27. **S**
- Name a health care agent and record his values and wishes while he can take full part, by the three-month review. In progress; target 2026-08-04. **S**

## Medication changes

- Started: Donepezil 5 mg oral tablet, one tablet by mouth each morning **S**

## Guideline basis

- Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001), American Academy of Neurology (Neurology)
- Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010), American Academy of Neurology (Neurology)
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025), Alzheimer's Association (Alzheimer's & Dementia)
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2025), Alzheimer's Association (Alzheimer's & Dementia)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026), Aether Forge

## Follow-up

- Three-month dementia review with the donepezil dose decision, the Zarit Burden Interview, and advance care planning. **S**
- Next scheduled visit 2026-08-04: three-month dementia review: donepezil, safety plan, caregiver burden, and advance care planning. **S**
